The European Paediatric Network for Haemophilia Management ( PedNet Registry)
NCT ID: NCT02979119
Last Updated: 2025-09-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
4000 participants
OBSERVATIONAL
2014-06-30
2039-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Haemophilia is a rare disease; to improve knowledge international collaboration is needed. Well-defined clinical data will be collected from complete cohorts in order to prevent selection bias.
Objective:
To collect data on bleeding during neonatal period, endogenous (genetic) and exogenous (treatment-related) determinants of inhibitor development and long term outcome.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
German Pediatric Hemophilia Research Database
NCT02912143
World Bleeding Disorders Registry
NCT03327779
World Bleeding Disorders Registry Pilot Study
NCT02776826
Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients
NCT02540187
Rare Bleeding Disorders in the Netherlands
NCT03347591
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Population:
Patients with haemophilia A and B with FVIII/IX levels of \<1 to 25% born between 1-1-2000 and 1-1-2040.
Intervention:
No intervention; only documentation of patient characteristics and parameters of routine patient care and outcome
Main outcome parameters:
Outcome: clinically relevant inhibitor development, bleeding pattern and joint status on physical examination and imaging.
Determinants: baseline FVIII/IX levels, measurement of inhibitory antibodies, family history, FVIII/IX gene mutation, details on replacement therapy (according to each infusion for the first 50 treatment days, and annually thereafter) and surgeries.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
* No burden for the patients. Well-defined clinical data will be collected from the medical files. Participating in this registry will not change the number of visits to the clinic. All outcome parameters that are collected (including laboratory results) are part of routine clinical care.
* Direct benefit is not to be expected. However, the direct interaction between centres that treat patients with rare diseases improves both clinical care and will result in better guidelines and as such may provide indirect benefit.
* Multicentre participation: haemophilia is a very rare condition. Therefore, collecting data on a multi-centre observational cohort is the only way to study this specific population.
* The registry concerns young boys and girls with haemophilia and cannot be performed in older patients, as \>90% of inhibitors occur develop during the first 50 exposure days, and the results of prophylactic replacement therapy are highly dependent on the initiation of this treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort I
Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX \<1%) haemophilia A or B, born from January 1st 2000 until December 31st 2009 who have been or are to be treated with coagulation proteins in one of the participating centres
No interventions assigned to this group
Cohort II
Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX \<1%) haemophilia A or B, born from January 1st 2010 until December 31st 2019 who have been or are to be treated with coagulation proteins in one of the participating centres
No interventions assigned to this group
Cohort III
Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX \<1%) haemophilia A or B, born from January 1st 2020 until December 31st 2029 who have been or are to be treated with coagulation proteins in one of the participating centres
No interventions assigned to this group
Cohort IV
Cohort IV Group/Cohort Description: Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX \<1%) haemophilia A or B, born from January 1st 2030 until December 31st 2039 who have been or are to be treated with coagulation proteins in one of the participating centres
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Factor VIII/ IX activity of \<1 to 25%
* Complete records of Factor treatment and bleeds
* Treated in one of the participating centres
Exclusion Criteria
* Informed consent not obtained
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
PedNet Haemophilia Research Foundation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gili Kenet
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gili Kenet, PhD, MD
Role: STUDY_DIRECTOR
The National Hemophilia Center Ministry of Health Sheba Medical Center Ramat Gan, Israel
Christoph Male, MD
Role: STUDY_CHAIR
Medical University of Vienna
Gili Kenet, PhD, MD
Role: PRINCIPAL_INVESTIGATOR
The National Hemophilia Center Ministry of Health Sheba Medical Center Ramat Gan, Israel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitäts-Klinik für Kinder- und Jugendheilkunde
Graz, , Austria
Medical University of Vienna - Department of Paediatrics
Vienna, , Austria
Service of Pediatric Haematology University Hospital Leuven
Leuven, , Belgium
Division of Hematology/Oncology Hôpital St Justine
Montreal, , Canada
Division of Haematology/Oncology Hospital for Sick Children
Toronto, , Canada
Haemophilia Comprehensive Care Centre, Centre for Thrombosis and Haemostasis Children's University Hospital Brno
Brno, , Czechia
Department of Paediatric Haematology/oncology - University Hospital Motol
Prague, , Czechia
Department of Pediatrics Århus Kommunehospital Skejby Sygehus
Aarhus, , Denmark
Children's Hospital Helsinki University Hospital
Helsinki, , Finland
Service Hématologique Centre Regional Traitement d'Hemophilie Bicetre
Le Kremlin-Bicêtre, , France
Service d'Hématologie Pédiatrique Hôpital Universitaire La Timone
Marseille Cedex-05, , France
Centre de traitement des hémophiles Hôpital Universitaire Purpan
Toulouse, , France
Charité Campus Virchow Klinikum, Klinik für Pädiatrie m.S. Onkologie und Hämatologie
Berlin, , Germany
Department of Internal Medicine, Hemophilia Treatment Center, Vivantes Klinikum im Friedrichshain
Berlin, , Germany
Institut für Experimentelle Hämatologie und Transfusionsmedizin Universitätsklinikum Bonn
Bonn, , Germany
Klinik Bremen-Mitte Prof.-Hess-Kinderklinik
Bremen, , Germany
Hämophilie Zentrum Rhein Main
Frankfurt, , Germany
University Hospital Frankfurt & Goethe University - Clinical and Molecular Hemostasis, Department of Pediatrics
Frankfurt am Main, , Germany
Dr. v. Haunersches Kinderspital University of Munich
Munich, , Germany
Haemophilia-Haemostasis Unit St. Sophia Children's Hospital
Athens, , Greece
Children's Health Ireland (CHI) at Crumlin
Dublin, , Ireland
The National Hemophilia Center Sheba Medical Center, Tel Hashomer
Ramat Gan, , Israel
Azienda Ospedaliero Universitaria Careggi
Florence, , Italy
Gaslini Hospital
Genova, , Italy
A. Bianchi Bonomi Hemophilia and Thrombosis Centre IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, , Italy
Van Creveld Kliniek University Medical Center Utrecht
Utrecht, , Netherlands
Oslo University Hospital
Oslo, , Norway
Centro Hospitalar São João, S. Imuno-hemoterapia
Porto, , Portugal
Unitat Hemofilia Hospital Vall d'Hebron
Barcelona, , Spain
Unidad de Coagulopatías Hospital Universitario La Paz
Madrid, , Spain
Hospital General Unidad de Hemofilia 1 Sur Hospitales Universitarios Virgen del Rocio
Seville, , Spain
Unidad de Coagulopatias Congenitas Hospital Universitario la Fe
Valencia, , Spain
Lund University Hospital
Malmo, , Sweden
Department of Pediatrics, Clinic of Coag. Disorders Karolinska Hospital
Stockholm, , Sweden
Inselspital Bern, University Children's Hospital
Bern, , Switzerland
Birmingham Children's Hospital NHS Trust - Department of Haematology
Birmingham, , United Kingdom
Royal Hospital for Sick Children
Edinburgh, , United Kingdom
Department of Haematology Royal Hospital for Sick Children
Glasgow, , United Kingdom
Haemophila Center Great Ormond Street Hospital for Children
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Christoph Male, MD
Role: primary
Christel Van Geet, MD, PhD
Role: primary
Natalie Mathews, MD
Role: primary
Manuel Carcao, MD, PhD
Role: primary
Jan Blatny, MD, PhD
Role: primary
Ester Zapotocka, MD
Role: primary
Torben Stamm Mikkelsen, MD
Role: primary
Satu Langstrom, MD, PhD
Role: primary
Roseline d'Oiron, MD
Role: primary
Hervé Chambost, MD, PhD
Role: primary
Caroline Oudot, MD
Role: primary
Susanne Holzhauer, MD
Role: primary
Robert Klamroth, MD, PhD
Role: primary
Johannes Oldenburg, MD, PhD
Role: primary
Martina Bührlen, MD
Role: primary
Carmen Escuriola Ettingshausen, MD
Role: primary
Christoph Königs, MD, PhD
Role: primary
Martin Olivieri, MD
Role: primary
Helen Pergantou, MD
Role: primary
Beatrice Nolan, MD
Role: primary
Sarina Levy Mendelovich, MD
Role: primary
Giancarlo Castaman, MD
Role: primary
Angelo Claudio Molinari, MD
Role: primary
Corien Eckhardt, MD, PhD
Role: primary
Heidi Knüdsen, MD
Role: primary
Manuela Carvalho, MD
Role: primary
Olga Benítez Hidalgo, MD
Role: primary
Maria Theresa Alvarez Roman, MD
Role: primary
Ana Rosa Cid, MD
Role: primary
Nadine Gretenkort Andersson, MD, PhD
Role: primary
Susanna Ranta, MD
Role: primary
Mutlu Kartal-Kaess, MD
Role: primary
Jayashree Motwani, MD
Role: primary
Fernando Pinto, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
de Kovel M, van Haaster AC, Carcao M, Ranta S, Glosli H, Rivard GE, Kenet G, Kurnik K, Van Geet C, Carvalho M, Andersson NG, Kartal-Kaess M, Ljung R, van den Berg HM; PedNet Study Group. Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A: Data from the PedNet Study Group. Haemophilia. 2025 May;31(3):419-423. doi: 10.1111/hae.70035. Epub 2025 Mar 23.
Carcao M, Konigs C, Andersson NG, de Kovel M, de Boer-Verdonk E, Motwani J, Blatny J, Olivieri M, van den Berg M, Fischer K. Predictors of immune tolerance induction success in 231 children with severe hemophilia A with high-titer inhibitors - lessons learned from the PedNet prospective cohort study. J Thromb Haemost. 2025 Oct;23(10):3134-3147. doi: 10.1016/j.jtha.2025.07.010. Epub 2025 Jul 22.
Mendoza A, Rivas I, Hidalgo OB, Cid AR, Olivieri M, Ranta S, Labarque V, Andersson NG, de Kovel M, Alvarez-Roman MT. Impact of Family History of Haemophilia on Diagnosis, Management and Outcomes in Severe Haemophilia. Haemophilia. 2025 Jul;31(4):679-686. doi: 10.1111/hae.70018. Epub 2025 May 30.
Ranta S, Zapotocka E, Andersson NG, Fischer K, Kenet G, de Kovel M, Konigs C, Labarque V, Male C, Olivieri M, Motwani J. A survey on clinical practice in monitoring and management of bleeding in children with haemophilia A on emicizumab prophylaxis in the PedNet centres. Thromb Res. 2025 May;249:109307. doi: 10.1016/j.thromres.2025.109307. Epub 2025 Mar 19. No abstract available.
van den Berg HM, Gouw SC, van der Bom JG. Factor VIII products and inhibitors in severe hemophilia A. N Engl J Med. 2013 Apr 11;368(15):1457. doi: 10.1056/NEJMc1301995. No abstract available.
Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, Chambost H, Kurnik K, Liesner R, Petrini P, Platokouki H, Altisent C, Oldenburg J, Nolan B, Garrido RP, Mancuso ME, Rafowicz A, Williams M, Clausen N, Middelburg RA, Ljung R, van der Bom JG; PedNet and Research of Determinants of INhibitor development (RODIN) Study Group. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013 May 16;121(20):4046-55. doi: 10.1182/blood-2012-09-457036. Epub 2013 Apr 3.
Carcao MD, van den Berg HM, Ljung R, Mancuso ME; PedNet and the Rodin Study Group. Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A. Blood. 2013 May 9;121(19):3946-52, S1. doi: 10.1182/blood-2012-11-469403. Epub 2013 Mar 12.
Clausen N, Petrini P, Claeyssens-Donadel S, Gouw SC, Liesner R; PedNet and Research of Determinants of Inhibitor development (RODIN) Study Group. Similar bleeding phenotype in young children with haemophilia A or B: a cohort study. Haemophilia. 2014 Nov;20(6):747-55. doi: 10.1111/hae.12470. Epub 2014 Jun 3.
Fischer K, Ljung R, Platokouki H, Liesner R, Claeyssens S, Smink E, van den Berg HM. Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry. Haemophilia. 2014 Jul;20(4):e280-6. doi: 10.1111/hae.12448. Epub 2014 May 2.
Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, van Geet C, Kenet G, Makipernaa A, Molinari AC, Muntean W, Kobelt R, Rivard G, Santagostino E, Thomas A, van den Berg HM; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013 Jan 17;368(3):231-9. doi: 10.1056/NEJMoa1208024.
Andersson NG, Auerswald G, Barnes C, Carcao M, Dunn AL, Fijnvandraat K, Hoffmann M, Kavakli K, Kenet G, Kobelt R, Kurnik K, Liesner R, Makipernaa A, Manco-Johnson MJ, Mancuso ME, Molinari AC, Nolan B, Perez Garrido R, Petrini P, Platokouki HE, Shapiro AD, Wu R, Ljung R. Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment. Br J Haematol. 2017 Oct;179(2):298-307. doi: 10.1111/bjh.14844. Epub 2017 Jul 12.
Mancuso ME, Fischer K, Santagostino E, Oldenburg J, Platokouki H, Konigs C, Escuriola-Ettingshausen C, Rivard GE, Cid AR, Carcao M, Ljung R, Petrini P, Altisent C, Kenet G, Liesner R, Kurnik K, Auerswald G, Chambost H, Makipernaa A, Molinari AC, Williams M, van den Berg HM; European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal life MAnagement of children with INhibitors) Study Group. Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors. Thromb Haemost. 2017 Dec;117(12):2274-2282. doi: 10.1160/TH17-01-0059. Epub 2017 Dec 6.
Andersson NG, Chalmers EA, Kenet G, Ljung R, Makipernaa A, Chambost H; PedNet Haemophilia Research Foundation. Mode of delivery in hemophilia: vaginal delivery and Cesarean section carry similar risks for intracranial hemorrhages and other major bleeds. Haematologica. 2019 Oct;104(10):2100-2106. doi: 10.3324/haematol.2018.209619. Epub 2019 Feb 21.
van den Berg HM, Fischer K, Carcao M, Chambost H, Kenet G, Kurnik K, Konigs C, Male C, Santagostino E, Ljung R; PedNet Study Group. Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood. 2019 Jul 18;134(3):317-320. doi: 10.1182/blood.2019000658. Epub 2019 Jun 11. No abstract available.
Male C, Andersson NG, Rafowicz A, Liesner R, Kurnik K, Fischer K, Platokouki H, Santagostino E, Chambost H, Nolan B, Konigs C, Kenet G, Ljung R, Van den Berg M. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica. 2021 Jan 1;106(1):123-129. doi: 10.3324/haematol.2019.239160.
van den Berg HM, Mancuso ME, Konigs C, D'Oiron R, Platokouki H, Mikkelsen TS, Motwani J, Nolan B, Santagostino E; European Pediatric Network for Haemophilia Management (PedNet). ITI Treatment is not First-Choice Treatment in Children with Hemophilia A and Low-Responding Inhibitors: Evidence from a PedNet Study. Thromb Haemost. 2020 Aug;120(8):1166-1172. doi: 10.1055/s-0040-1713097. Epub 2020 Jun 22.
Andersson NG, Wu R, Carcao M, Claeyssens-Donadel S, Kobelt R, Liesner R, Makipernaa A, Ranta S, Ljung R; ICH study group. Long-term follow-up of neonatal intracranial haemorrhage in children with severe haemophilia. Br J Haematol. 2020 Jul;190(2):e101-e104. doi: 10.1111/bjh.16740. Epub 2020 Jun 9. No abstract available.
Platokouki H, Fischer K, Gouw SC, Rafowicz A, Carcao M, Kenet G, Liesner R, Kurnik K, Rivard GE, van den Berg HM. Vaccinations are not associated with inhibitor development in boys with severe haemophilia A. Haemophilia. 2018 Mar;24(2):283-290. doi: 10.1111/hae.13387. Epub 2017 Dec 15.
Khair K, Ranta S, Thomas A, Lindvall K; PedNet study group. The impact of clinical practice on the outcome of central venous access devices in children with haemophilia. Haemophilia. 2017 Jul;23(4):e276-e281. doi: 10.1111/hae.13241. Epub 2017 May 24.
Hashemi SM, Fischer K, Moons KGM, van den Berg HM; PedNet Study group. Validation of the prediction model for inhibitor development in PUPs with severe haemophilia A. Haemophilia. 2016 Mar;22(2):e116-e118. doi: 10.1111/hae.12895. Epub 2016 Feb 8. No abstract available.
Ranta S, Motwani J, Blatny J, Buhrlen M, Carcao M, Chambost H, Escuriola C, Fischer K, Kartal-Kaess M, de Kovel M, Kenet G, Male C, Nolan B, d'Oiron R, Olivieri M, Zapotocka E, Andersson NG, Konigs C. Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres. Haemophilia. 2023 Sep;29(5):1291-1298. doi: 10.1111/hae.14847. Epub 2023 Aug 30.
Labarque V, Mancuso ME, Kartal-Kaess M, Ljung R, Mikkelsen TS, Andersson NG. F8/F9 variants in the population-based PedNet Registry cohort compared with locus-specific genetic databases of the European Association for Haemophilia and Allied Disorders and the Centers for Disease Control and Prevention Hemophilia A or Hemophilia B Mutation Project. Res Pract Thromb Haemost. 2023 Jan 10;7(1):100036. doi: 10.1016/j.rpth.2023.100036. eCollection 2023 Jan.
Fischer K, Carcao M, Male C, Ranta S, Pergantou H, Kenet G, Kartal-Kaess M, Konigs C, Carvalho M, Alvarez MT, Brakenhoff T, Chambost H, van den Berg HM. Different inhibitor incidence for individual factor VIII concentrates in 1076 previously untreated patients with severe hemophilia A: data from the PedNet cohort. J Thromb Haemost. 2023 Mar;21(3):700-703. doi: 10.1016/j.jtha.2022.11.020. Epub 2022 Dec 22. No abstract available.
Ljung R, de Kovel M, van den Berg HM; PedNet study group. Primary prophylaxis in children with severe haemophilia A and B-Implementation over the last 20 years as illustrated in real-world data in the PedNet cohorts. Haemophilia. 2023 Mar;29(2):498-504. doi: 10.1111/hae.14729. Epub 2022 Dec 26.
Schmidt DE, Michalopoulou A, Fischer K, Motwani J, Andersson NG, Pergantou H, Ranta S; PedNet Study Group. Long-term joint outcomes in adolescents with moderate or severe haemophilia A. Haemophilia. 2022 Nov;28(6):1054-1061. doi: 10.1111/hae.14636. Epub 2022 Aug 4.
Alvarez-Roman MT, Kurnik K; PedNet Study Group. Care for children with haemophilia during COVID-19: Data of the PedNet study group. Haemophilia. 2021 Jul;27(4):e537-e539. doi: 10.1111/hae.14286. Epub 2021 Mar 8. No abstract available.
Minna K, Anne M, Beatrice N, Rainer K, Susanna R. Correction of haemostasis can be reduced to four days for CVAD implantation in severe haemophilia A patients: Data from the PedNet study group. Haemophilia. 2021 May;27(3):392-397. doi: 10.1111/hae.14231. Epub 2021 Mar 21.
Andersson NG, Labarque V, Letelier A, Mancuso ME, Buhrlen M, Fischer K, Kartal-Kaess M, Koskenvuo M, Mikkelsen T, Ljung R; PedNet study group. Novel F8 and F9 gene variants from the PedNet hemophilia registry classified according to ACMG/AMP guidelines. Hum Mutat. 2020 Dec;41(12):2058-2072. doi: 10.1002/humu.24117. Epub 2020 Oct 14.
Jonker CJ, Oude Rengerink K, Hoes AW, Mol PGM, van den Berg HM. Inhibitor development in previously untreated patients with severe haemophilia: A comparison of included patients and outcomes between a clinical study and a registry-based study. Haemophilia. 2020 Sep;26(5):809-816. doi: 10.1111/hae.14100. Epub 2020 Jul 6.
Andersson NG, Labarque V, Kartal-Kaess M, Pinto F, Mikkelsen TS, Ljung R, Group PS. Factor VIII genotype and the risk of developing high-responding or low-responding inhibitors in severe hemophilia A: data from the PedNet Hemophilia Cohort of 1,202 children. Haematologica. 2024 Apr 1;109(4):1293-1296. doi: 10.3324/haematol.2023.284095. No abstract available.
Fischer K, Kenet G, Kurnik K, Carcao M, Oldenburg J, Stamm-Mikkelsen T, Cid Haro AR, Koskenvuo M, Blatny J, Konigs C. Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU. Blood Adv. 2024 Jan 23;8(2):369-377. doi: 10.1182/bloodadvances.2023011442.
van der Zwet K, de Kovel M, Motwani J, van Geet C, Nolan B, Glosli H, Escuriola Ettingshausen C, Konigs C, Kenet G, Fischer K; PedNet Investigators. Bleeding control improves after switching to emicizumab: Real-world experience of 177 children in the PedNet registry. Haemophilia. 2024 May;30(3):685-692. doi: 10.1111/hae.15015. Epub 2024 Apr 5.
de Kovel MS, Escuriola-Ettingshausen C, Konigs C, Ranta S, Fischer K; PedNet Study Group. Bleeding phenotype according to factor level in 825 children with nonsevere hemophilia: data from the PedNet cohort. J Thromb Haemost. 2024 Sep;22(9):2460-2469. doi: 10.1016/j.jtha.2024.05.030. Epub 2024 Jun 10.
Related Links
Access external resources that provide additional context or updates about the study.
Website of the PedNet Registry
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Version 6.4 November 2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.